Pheochromocytoma of the bladder - Report of two new cases

Report of two cases of pheochromocytoma of the bladder to note its variable and misleading features. Pheochromocytoma of the bladder is a rare disease, that develops in the bladder from sympathetic plexus. This kind of tumor accounted for 10 to 15% of paragangliomas, 1% of pheochrocytomas and 0.1% of bladder tumors. This disease is more common at age 40 and in women than men (3/1). The diagnosis is based on biochemical tests and current imaging techniques, particularly ultrasonography and computerized tomography. Careful follow-up is mandatory because the tumors may progress to malignancy

New advances in molecular biology of prostate cancer

Prostate cancer is the most common detected cancer and the second cause of mortality in male patient aged > 45 in many countries in the world. New advances in molecular biology and genetics in association with great achievements in biological technology permit identily the creation and the process of prostate cancer in various profiles. The role of inflammation in the onset of prostate cancer is opened slightly. Research permits to predict new markers and to make promises for new treatments efficacy progressively against this dangerous disease of increasing concern

Inhibition of enzym cyclooxygenase-2 in the treatment urinary cancer

As clinical study showed that COX-2 is strengthened in the angiogenesis, apoptosis, invasive and increasing immunization in the process of tumor progress. The first result of use inhibitor COX-2 has potential in prevention and treatment of tumor. Use COX-2 in progress of prostate cancer as metastasis tumor and be low isolated. Use COX-2 in bladder tumor without response with BCG and after cut off bladder. Use COX-2 in metastasis kidney tumor or have high risk in Von Hippel-Lindau

Genetic factors in prostate cancer and their clinical applications

Genetic factor is considered a special risk in prostate cancer. This article introduced some investigations of genes in prostate cancer. Genetic mechanisms in this disease may be complicated and diversified due to mutations or minor variations but major impact. It is shown current attitude of clinicians for hereditary prostate cancer

Genetics and renal cancer

Nowadays, scientists are focus on studying the hereditary basic of renal cancer in order to detect early renal cancer and initially apply some treatment methods at molecular level. There are 4 types of renal cancer: Firstly, clear cell renal carcinoma is the most common one. Secondly, hereditary papillary renal carcinoma type I (HPRC) generated from epithelium of distal convoluted tubules which was discovered by Zbar in 1944, often occurs after 40 year old. Thirdly, hereditary chromophobe renal carcinoma and oncocytome which were described by Thoenes in 1985 and by Zipell in 1942 respectively. Hereditary oncocytome was found by Weirich in 1998. Fourthly, hereditary leiomyomatosis renal cell carcinoma (HLRCC) and multiple cutaneous leiomyoma (MCL) belonging to papillary renal carcinoma type II is very malignant and metastatic